Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296285 | 0.89 | ADRB1 (0.44) | ADRB1SMN1; SMN2ALDH1A1HPGDALOX5 | |
| SCHEMBL9706409 | 0.79 | ALDH1A1 (0.40) | ADRB1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10199935 | 0.77 | NPSR1 (0.32) | ALDH1A1HPGDMAPTPOLBL3MBTL1 | |
| SCHEMBL6653606 | 0.77 | TTR (0.39) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL9030269 | 0.75 | HSD17B10 (0.45) | SMN1; SMN2ALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL3153767 | 0.72 | MAPT (0.40) | ADRB1SMN1; SMN2ALDH1A1ALOX5MAPT | |
| SCHEMBL1156328 | 0.71 | ALDH1A1 (0.48) | ADRB1SMN1; SMN2ALDH1A1HPGDALOX5 | |
| Hydrochloric Acid SCHEMBL1155766 | 0.70 | ALDH1A1 (0.47) | ADRB1SMN1; SMN2ALDH1A1HPGDALOX5 | |
| SCHEMBL22753233 | 0.68 | ADRB1 (0.47) | ADRB1SMN1; SMN2ALDH1A1HPGDALOX5 | |
| SCHEMBL7789812 | 0.68 | ALDH1A1 (0.41) | ADRB1SMN1; SMN2ALDH1A1HPGDALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115192711-A | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-104758291-B | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2020-03-03 | — | — | CN | disclosed |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2019-06-20 | — | — | US | disclosed |
| EP-2427193-B1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORP (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-9119822-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150240226-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | BP CORP NORTH AMERICA INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-8962800-B2 | Nucleic acids and proteins and methods for making and using them | BP CORPORATION NORTH AMERICA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2139475-B1 | PDE7 inhibitors for use in the treatment of movement disorders | OMEROS CORP (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | OMEROS CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2004037791-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-05-06 | — | — | WO | disclosed |
| US-6620792-B1 | Monosialoganglioside GM1 or a derivative thereof, namely, the inner ester AGF2 and the methyl ester AGF4, suitable for the treatment of Parkinson's disease. A further object of the present invention is a therapy for Parkinson's Disease | FIDIA S.P.A. (IT) | 2003-09-16 | — | — | US | disclosed |
| EP-0770389-B1 | Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease | FIDIA FARMACEUTICI (IT) | 2001-09-26 | — | — | EP | disclosed |
| EP-0770389-A1 | Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease | FIDIA S.p.A. (IT) | 1997-05-02 | — | — | EP | disclosed |
| EP-0630250-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING MONOSIALOGANGLIOSIDE GM 1? OR A DERIVATIVE THEREOF SUITABLE FOR THE TREATMENT OF PARKINSON'S DISEASE | FIDIA S.p.A. (IT) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993017691-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING MONOSIALOGANGLIOSIDE GM1 OR A DERIVATIVE THEREOF SUITABLE FOR THE TREATMENT OF PARKINSON'S DISEASE | FIDIA S.P.A. (IT) | 1993-09-16 | — | — | WO | disclosed |
| US-5187162-A | Methods of treating neurodegenerative conditions | GENSIA PHARMACEUTICALS (US) | 1993-02-16 | — | — | US | disclosed |
| EP-0491792-A4 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | — | 1992-12-02 | — | — | EP | disclosed |
| EP-0491792-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | GENSIA, INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| WO-1991004032-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | GENSIA PHARMACEUTICALS, INC. (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150240226-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | POLN, POLM, POLI | ADRB1 4734/4885SMN1; SMN2 1508/4885ALDH1A1 2292/4885 |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | ADRB1 1522/4885SMN1; SMN2 390/4885ALDH1A1 1653/4885 |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | PARK7, PDE7B, PDE7A | ADRB1 1522/4885SMN1; SMN2 390/4885ALDH1A1 1653/4885 |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | ADRB1 1522/4885SMN1; SMN2 390/4885ALDH1A1 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.